These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28223667)

  • 1. [Molecular Diagnosis and Treatment of HBOC Syndrome].
    Miki Y
    Gan To Kagaku Ryoho; 2017 Feb; 44(2):102-106. PubMed ID: 28223667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 3. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
    Meaney-Delman D; Bellcross CA
    Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
    Mehemmai C; Cherbal F; Hamdi Y; Guedioura A; Benbrahim W; Bakour R; Abdelhak S
    Pathol Oncol Res; 2020 Apr; 26(2):715-726. PubMed ID: 30715675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and Treatment of HBOC Syndrome by a Breast Surgical Oncologist].
    Kida K; Murai M; Yamauchi H
    Gan To Kagaku Ryoho; 2017 Feb; 44(2):111-115. PubMed ID: 28223669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
    Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
    Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning.
    Fanale D; Pivetti A; Cancelliere D; Spera A; Bono M; Fiorino A; Pedone E; Barraco N; Brando C; Perez A; Guarneri MF; Russo TDB; Vieni S; Guarneri G; Russo A; Bazan V
    Crit Rev Oncol Hematol; 2022 Apr; 172():103626. PubMed ID: 35150867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted sequencing for hereditary breast and ovarian cancer in BRCA1/2-negative families reveals complex genetic architecture and phenocopies.
    Plowman JN; Matoy EJ; Uppala LV; Draves SB; Watson CJ; Sefranek BA; Stacey ML; Anderson SP; Belshan MA; Blue EE; Huff CD; Fu Y; Stessman HAF
    HGG Adv; 2024 Jul; 5(3):100306. PubMed ID: 38734904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications].
    Koual M; Perkins G; Delanoy N; Crespel C; Medioni J; Nguyen-Xuan HT; Douay-Hauser N; Blons H; Le Frère-Belda MA; Molière D; Achen G; Nos C; Balaya V; Montero R; Laurent-Puig P; Bats AS
    Ann Pathol; 2020 Apr; 40(2):70-77. PubMed ID: 32046878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
    De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
    Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
    Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
    Takahashi M; Chiba N; Shimodaira H; Yoshino Y; Mori T; Sumii M; Nomizu T; Ishioka C
    Breast Cancer; 2017 Mar; 24(2):336-340. PubMed ID: 27271530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
    Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.
    Hoang LN; Gilks BC
    Adv Anat Pathol; 2018 Mar; 25(2):85-95. PubMed ID: 28914618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
    Ryu JM; Nam SJ; Kim SW; Lee JE; Chae BJ; Lee SK; Yu J
    Jpn J Clin Oncol; 2020 Feb; 50(2):104-113. PubMed ID: 31926487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
    Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
    Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.